Equities Analysts Offer Predictions for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB) – Equities researchers at Zacks Research cut their Q1 2026 earnings estimates for shares of Biogen in a research note issued to investors on Wednesday, March 12th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings of $3.49 per share for the quarter, down from their previous estimate of $3.59. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q2 2026 earnings at $4.30 EPS, Q3 2026 earnings at $4.07 EPS, Q4 2026 earnings at $4.09 EPS, FY2026 earnings at $15.96 EPS and FY2027 earnings at $16.84 EPS.

BIIB has been the topic of several other reports. Truist Financial decreased their target price on shares of Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Bank Of America (Bofa) decreased their price objective on shares of Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 11th. Wells Fargo & Company decreased their price objective on shares of Biogen from $165.00 to $140.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 13th. Wolfe Research assumed coverage on shares of Biogen in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Robert W. Baird boosted their price objective on shares of Biogen from $294.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, Biogen currently has a consensus rating of “Hold” and a consensus target price of $213.33.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $139.44 on Friday. The firm has a market capitalization of $20.41 billion, a P/E ratio of 12.46, a PEG ratio of 1.51 and a beta of 0.01. Biogen has a one year low of $128.51 and a one year high of $238.00. The company’s fifty day moving average is $143.09 and its two-hundred day moving average is $164.57. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

Insider Activity

In related news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. This represents a 43.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Biogen

A number of institutional investors and hedge funds have recently bought and sold shares of BIIB. Larson Financial Group LLC increased its position in Biogen by 640.9% during the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 141 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in Biogen during the 4th quarter worth approximately $25,000. Colonial Trust Co SC increased its position in Biogen by 9,300.0% during the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 186 shares in the last quarter. OFI Invest Asset Management acquired a new stake in Biogen during the 4th quarter worth approximately $32,000. Finally, Ashton Thomas Securities LLC acquired a new stake in Biogen during the 3rd quarter worth approximately $33,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.